TABLE 1.
Baseline demographic and clinical characteristics of subjects
| Placebo (n = 25) | Quarter‐dose (n = 25) | Third‐dose (n = 25) | Half‐dose (n = 25) | Amlodipine 5 mg (n = 26) | Amlodipine 10 mg (n = 25) | Telmisartan 80 mg (n = 25) | Total (n = 176) | |
|---|---|---|---|---|---|---|---|---|
| Age (years) | 59.96 ± 13.19 | 63.88 ± 8.45 | 58.84 ± 10.15 | 64.16 ± 6.68 | 61.65 ± 9.67 | 59.88 ± 10.82 | 58.12 ± 9.12 | 60.93 ± 9.98 |
| Age group (years) | ||||||||
| <65 | 13 (52.00) | 10 (40.00) | 17 (68.00) | 9 (36.00) | 14 (53.85) | 15 (60.00) | 18 (72.00) | 96 (54.55) |
| ≥65 | 12 (48.00) | 15 (60.00) | 8 (32.00) | 16 (64.00) | 12 (46.15) | 10 (40.00) | 7 (28.00) | 80 (45.45) |
| Gender | ||||||||
| Male | 18 (72.00) | 10 (40.00) | 20 (80.00) | 15 (60.00) | 18 (69.23) | 17 (68.00) | 17 (68.00) | 115 (65.34) |
| Female | 7 (28.00) | 15 (60.00) | 5 (20.00) | 10 (40.00) | 8 (30.77) | 8 (32.00) | 8 (32.00) | 61 (34.66) |
| Height (cm) | 165.53 ± 9.47 | 159.38 ± 8.83 | 165.37 ± 6.93 | 163.03 ± 8.49 | 166.76 ± 9.22 | 165.32 ± 8.88 | 165.08 ± 7.96 | 164.37 ± 8.74 |
| Weight (kg) | 70.70 ± 12.31 | 63.18 ± 10.21 | 72.92 ± 11.08 | 68.64 ± 12.38 | 71.42 ± 13.40 | 74.34 ± 14.24 | 71.32 ± 15.10 | 70.36 ± 13.00 |
| Body mass index (kg/m2) | 25.71 ± 3.29 | 24.82 ± 3.07 | 26.65 ± 3.50 | 25.80 ± 4.18 | 25.55 ± 3.28 | 27.02 ± 3.62 | 25.97 ± 3.95 | 25.93 ± 3.58 |
| Smoking | ||||||||
| Non‐smoker | 16 (64.00) | 18 (72.00) | 13 (52.00) | 17 (68.00) | 12 (46.15) | 14 (56.00) | 13 (52.00) | 103 (58.52) |
| Ex‐smoker | 5 (20.00) | 4 (16.00) | 8 (32.00) | 2 (8.00) | 7 (26.92) | 10 (40.00) | 4 (16.00) | 40 (22.73) |
| Smoker | 4 (16.00) | 3 (12.00) | 4 (16.00) | 6 (24.00) | 7 (26.92) | 1 (4.00) | 8 (32.00) | 33 (18.75) |
| Duration of disease (years)a | 10.35 ± 6.05 | 10.24 ± 7.04 | 9.78 ± 4.64 | 10.15 ± 8.24 | 11.90 ± 9.04 | 8.29 ± 7.89 | 9.71 ± 7.68 | 10.07 ± 7.30 |
| Antihypertensives | ||||||||
| Yes | 24 (96.00) | 22 (88.00) | 24 (96.00) | 23 (92.00) | 22 (84.62) | 20 (80.00) | 23 (92.00) | 158 (89.77) |
| No | 1 (4.00) | 3 (12.00) | 1 (4.00) | 2 (8.00) | 4 (15.38) | 5 (20.00) | 2 (8.00) | 18 (10.23) |
| History of diabetes | ||||||||
| Yes | 4 (16.00) | 5 (20.00) | 9 (36.00) | 7 (28.00) | 7 (26.92) | 5 (20.00) | 3 (12.00) | 40 (22.73) |
| No | 21 (84.00) | 20 (80.00) | 16 (64.00) | 18 (72.00) | 19 (73.08) | 20 (80.00) | 22 (88.00) | 136 (77.27) |
| Baseline MSSBP | ||||||||
| Mean ± SD | 148.15 ± 8.45 | 151.77 ± 12.65 | 149.65 ± 12.45 | 153.17 ± 10.39 | 150.98 ± 10.30 | 149.87 ± 12.89 | 151.38 ± 10.55 | |
| Baseline MSDBP | ||||||||
| Mean ± SD | 89.77 ± 5.88 | 90.76 ± 7.97 | 91.30 ± 9.98 | 91.96 ± 8.84 | 93.68 ± 8.96 | 90.80 ± 10.12 | 94.38 ± 10.15 | |
| Baseline pulse rate | ||||||||
| Mean ± SD | 70.04 ± 11.27 | 73.20 ± 9.46 | 75.80 ± 11.08 | 76.20 ± 12.98 | 78.15 ± 12.42 | 74.00 ± 16.29 | 76.44 ± 7.70 | |
Data are presented as mean ± standard deviation or number (%). The percentage was calculated using the number of subjects for each parameter in each group as a denominator. MSDBP, mean sitting diastolic BP; MSSBP, mean sitting systolic BP; SD, standard deviation.
aDuration of disease: (date of screening − date of diagnosis of hypertension)/365.25.